Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA May Scrap Clinical Study Report Disclosure For New Drug Approvals

Executive Summary

The pilot project former Commissioner Gottlieb championed found only one sponsor interested in participating.

You may also be interested in...

US FDA Commissioner Race: Transparency Comes To Forefront With Study Of Refuse-To-File Letters

Of the two main contenders to lead FDA, Josh Sharfstein is seen as much more likely to open up review decisions to public scrutiny, while Janet Woodcock might be a vote for the status quo and more deferential to industry concerns.

Clinical Study Report Release Could Compromise Patient Privacy, Groups Say

US FDA's plan to post CSRs may also inadvertently release confidential commercial information, agency is warned by industry groups.

US FDA's Integrated Review Document Would Dramatically Downsize Public Information

Interdisciplinary review template provides efficient summaries of data, but without the insight into regulatory thinking made possible by disclosure of decisional memoranda, subject area reviews, and meeting minutes.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts